

## LETTER TO THE EDITOR

# ***DLST* mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodeling**

Dear Editor,

Of all human tumors, pheochromocytomas and paragangliomas (PPGLs) have the highest heritability rate. Over 15% of PPGLs harbor mutations in genes encoding tricarboxylic acid (TCA) cycle-related enzymes that cause oncometabolite accumulation and drive tumorigenesis via metabolic adaptation to hypoxia and global hypermethylation [1]. The dihydrolipoamide S-succinyltransferase (*DLST*) gene was recently described as a new PPGL susceptibility gene [2]. *DLST* is a component of the 2-oxoglutarate dehydrogenase (OGDH) complex (OGDHc) that catalyzes the conversion of alpha-ketoglutarate to succinyl-coenzyme A (SucCoA) in the TCA cycle. It also plays an understudied role in protein succinylation, a highly conserved post-translational modification (PTM) involving succinyl group transfer from SucCoA to protein lysine residues [3]. Succinylation causes major chemical and structural changes to proteins and has been linked to the development of diseases, including cancer [4, 5]. Here, we further characterized *DLST*-mutated PPGLs, explored the molecular mechanisms underlying their tumorigenesis, and examined the impact of *DLST* mutations on the succinylome.

Transcriptome analysis was performed for PPGLs carrying the recurrent *DLST*-p.G374E mutation and a PPGL carrying the *DLST*-p.Y422C variant, whose deleterious effect was supported by a comprehensive study (Supplementary Figure S1). Hierarchical clustering revealed that *DLST*-

mutated tumors showed a pseudohypoxic transcriptional profile (Figure 1A), supported by the expression of canonical hypoxia-related genes (Supplementary Figure S2). Conversely, unsupervised clustering of DNA methylation data separated *DLST*-mutated tumors from PPGLs with mutations of other TCA cycle-related genes (Figure 1B), suggesting that *DLST*-mutated tumors lacked a hypermethylated phenotype. Thus, we investigated alternative tumorigenic mechanisms.


Structural modeling of the recently described homooligomeric *DLST* 24-mer [6] showed that glycine 374 is physically close to aspartic acid 428 of a nearby *DLST* monomer (Figure 1C, left panel). The *DLST*-p.G374E mutation substitutes this glycine with a glutamic acid, potentially introducing a repulsive interaction between the two anionic side chains that could alter the oligomer's structure. Conversely, the *DLST*-p.Y422C mutation could disrupt a likely interaction between tyrosine 422 and threonine 383 from an adjacent *DLST* monomer (Figure 1C, right panel), altering the substrate pocket's three-dimensional conformation. *DLST* mutations identified in PPGL patients thus likely alter the homooligomeric *DLST* assembly and hence the native structure of the OGDHc.

To determine whether *DLST* alterations may affect the cellular succinylome, mass spectrometry was applied to previously generated *DLST* knockout (KO) H838 cell lines into which *DLST* constructs, including the wild-type (WT), the two aforementioned PPGL-causing mutants, and the catalytically dead p.H424A mutant [2] were stably introduced (Supplementary Figure S3A-B). *DLST*-KO cells exhibited dramatically reduced succinylation levels (Figure 1D, Supplementary Table S1) that were not caused by reduced protein abundance (Supplementary Figure S3C). The number of hyposuccinylated lysines differed between proteins, ranging from 1 to 20 (Supplementary Figure S3D). Moreover, hyposuccinylated proteins were involved in multiple pathways and mapped to all cellular

**Abbreviations:** PPGL, pheochromocytoma and paraganglioma; TCA, tricarboxylic acid; OGDH, 2-oxoglutarate dehydrogenase; OGDHc, oxoglutarate dehydrogenase complex; SucCoA, succinyl-coenzyme A; PTM, post-translational modification; KEGG, Kyoto Encyclopedia of Genes and Genomes; DLD, dihydrolipoamide dehydrogenase; NADH, nicotinamide adenine dinucleotide reduced; RNA-Seq, RNA sequencing; LCL, lymphoblastoid cell line; SDH, succinate dehydrogenase; NES, normalized enrichment scores; *DLST*, dihydrolipoamide S-succinyltransferase; KEGG, Kyoto Encyclopedia of Genes and Genomes; KO, knockout; WT, wild-type.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Cancer Communications* published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.



**FIGURE 1** PPGL-causing *DLST* mutations remodel the cellular succinylome and up-regulate the hypoxic pathway. **(A)** Unsupervised clustering of transcriptomic data (z-scores) for genes expressed differentially in PPGLs (Burnichon *et al.* 2011) grouped *DLST*-mutated tumors (shown in green) with cases featuring *SDH/VHL/EPAS1* (in blue, red, and purple, respectively) mutations (Cluster 1) and separately from Cluster 2 PPGLs (tumors carrying mutations in kinase signaling-related genes; in black), evidencing their pseudohypoxic nature. **(B)** Hierarchical clustering using DNA methylation data from a list of probes found differentially methylated in *SDHB*- or *FH*-mutated tumors showing a CpG island methylator phenotype (Ricketts CJ *et al.* PLoS One. 2022;17(12):e0278108), separated *DLST*-mutated tumors (green)

compartments (Supplementary Figure S3E, Supplementary Table S2), indicating a widespread down-regulation of succinylation. These findings enable us to experimentally link the absence of DLST to a profound decrease in this PTM. Although succinylation was once believed to be a pH-dependent non-enzymatic reaction regulated by donor (SucCoA) concentration, Gibson *et al.* [7] found that succinylation efficiency increased in the presence of  $\alpha$ -ketoglutarate and the OGDHc, suggesting that OGDHc could catalyze the succinylation of proteins. Our results support the role of DLST (and hence the OGDHc) as a major regulator of protein succinylation.

Compared to DLST-WT cells, those expressing DLST-p.G374E and DLST-p.H424A exhibited global hyposuccinylation, while cells expressing DLST-p.Y422C exhibited significant but more limited hyposuccinylation (Figure 1E-G, Supplementary Table S3). Some proteins with multiple down-regulated succinylation sites in DLST G374E cells were involved in the metabolic Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, such as the TCA cycle and glycolysis/gluconeogenesis (Figure 1H). Overall, cells carrying PPGL-causing *DLST* mutations exhibited hyposuccinylation of mitochondrial proteins, which was particularly pronounced in G374E-carrying cells (Supplementary Figure S4A). Changes in mitochondrial succinylation were validated in PPGL tumors using anti-succinyllysine immunohistochemistry: *DLST*-mutated tumors exhibited diffuse cytoplasmic staining, whereas PPGLs with mutations in other susceptibility

genes had granular and perinuclear succinylation patterns (Figure 1I). These results suggest that *DLST* mutations remodeled the cellular succinylome, causing mitochondrial hyposuccinylation and potentially altering the function of key proteins in PPGL development. Numerous metabolic enzymes are regulated by succinylation, either modulating their activity, degradation, or ability to interact with other proteins. For example, desuccinylation of the succinate dehydrogenase complex flavoprotein subunit A was reported to inhibit its enzymatic activity and promote clear cell renal cell carcinoma cell proliferation in vitro, and GLS desuccinylation protected it from ubiquitin-mediated degradation, promoting breast tumorigenesis [8]. Overall, histone succinylation was reduced by DLST-KO and was not fully restored to WT levels upon reintroducing DLST mutants (Supplementary Figure S4B, Supplementary Table S4). The molecular consequences of OGDHc-mediated histone succinylation have been described [4], but further studies are needed to unravel the implications of hyposuccinylation of specific histone residues.

Immunofluorescence staining showed that all DLST protein variants were mainly localized in the mitochondria regardless of mutations (Figure 1J), though they were also identified in other compartments by immunoblotting (Figure 1K). Of the other OGDHc components, dihydrolipoamide dehydrogenase (DLD) was localized in the mitochondria but was also present in the nucleus, while OGDH was generally found in mitochondria but

from hypermethylated tumors carrying mutations in SDH genes (blue). (C) Structure of DLST's homooligomeric 24-mer. Three DLST monomers are highlighted in dark blue, yellow and purple. The upper panels show the structure of DLST WT, while the bottom left and bottom right panels show the p.G374E and p.Y422C mutants, respectively. SucCoA denotes Succinyl-CoA (only the succinyl group is shown). (D-G) Volcano plots showing the number of differentially succinylated sites ( $\text{Log}_2\text{FC} < -1$  or  $> 1$ ,  $P < 0.05$ ) in DLST KO (D), DLST H424A (E), DLST G374E (F), and DLST Y422C (G) cells when compared to DLST WT cells. Blue, red and grey dots represent differentially hyposuccinylated sites, differentially hypersuccinylated sites, and non-significantly succinylated sites and/or with a  $\text{Log}_2\text{FC}$  between -1 and 1, respectively. (H) Representation of sites exhibiting significant differential succinylation (colored circles) in TCAc enzymes (left panel) and the Glycolysis/Gluconeogenesis pathway (right panel) when comparing DLST G374E and WT DLST cells. Both pathways exhibit global hyposuccinylation (blue color). (I) Anti-succinyllysine immunohistochemistry images of PPGLs harboring the *DLST* mutations p.Y422C (left top) and p.G374E (left bottom) and known mutations in other susceptibility genes as controls (right). The granular pattern and perinuclear staining observed in the images on the right suggest mitochondrial staining, whereas cells from *DLST*-mutated PPGLs exhibit more homogeneous cytoplasmic staining. The tumor harboring the p.Y422C *DLST* mutation (top left) has an intermediate pattern with fewer granules and some perinuclear staining, in accordance with proteomic succinylation data obtained using our cell model. (J) Immunofluorescence analysis of the different cell lines showing that DLST (green) colocalizes with the Mitotracker dye (red, MITO in the figure) and is thus predominantly localized in the mitochondria regardless of its mutations in all cells other than DLST KO cells lacking the DLST protein. Nuclei are stained in blue with DAPI. (K) Immunoblotting assay showing that DLST is present in the cytosol and nucleus compartments as well as the mitochondria-enriched fraction (named mitochondria in the figure) regardless of PPGL-causing mutations. OGDH levels are significantly reduced in DLST KO cells lacking DLST. GAPDH and TBP (nucleus) were used as loading controls, and COXIV as a mitochondrial marker. (L) Representation of normalized enrichment scores (NES) relative to DLST WT cells for the GSEA Hallmark gene sets of Hypoxia, Glycolysis and Oxidative phosphorylation in cells harboring DLST alterations (from left to right: DLST H424A, DLST G374E, DLST Y422C, DLST KO and LCL-G374E).

Abbreviations: PPGL, pheochromocytoma and paraganglioma; SucCoA, succinyl coenzyme A; TCAc, tricarboxylic acid cycle; DAPI, 4',6-diamidino-2-phenylindole, dihydrochloride; NES, normalized enrichment score; GSEA, gene set enrichment analysis; LCL, lymphoblastoid cell line; Succ-K IHC, succinylated lysine immunohistochemistry;  $\text{Log}_2\text{FC}$ ,  $\text{Log}_2$  fold change.

was absent in DLST-KO cells (Supplementary Figure S5). The low OGDH levels in DLST-KO cells were confirmed by immunoblotting (Figure 1K), suggesting that without DLST, OGDHc assembly is impaired and OGDH is degraded, consistent with the high OGDH degradation rates observed in the presence of *OGDH* mutations causing protein structural instability [9]. This result suggests that DLST plays a key role in OGDHc assembly, supporting the proposed stepwise assembly mechanism in which the stronger OGDH-DLST interaction forms before DLD is anchored [6]. Immunoblotting revealed that OGDHc assembly was unaffected by PPGL-causing *DLST* mutations, but a significant decrease in NADH production demonstrated the mutations' profound effect on OGDHc activity (Supplementary Figure S6). Overall, these findings showed that *DLST* mutations might not affect OGDHc assembly or subcellular location but impair its enzymatic activity.

Gene set enrichment analysis of RNA-sequencing data showed that when compared to DLST-WT cells, the hallmark gene sets of hypoxia and glycolysis were up-regulated, while the oxidative phosphorylation set was down-regulated in all cell lines carrying *DLST* alterations, including a lymphoblastoid cell line derived from a patient with the *DLST*-p.G374E mutation (Figure 1L, Supplementary Figure S7). This link between *DLST* mutations and hypoxia/glycolysis pathway up-regulation was confirmed by functional studies showing differences in glucose-dependent growth, oxygen consumption and ATP production in cells carrying *DLST* alterations (Supplementary Figure S8). However, DNA methylation profiling revealed no statistically significant differences between the H838 cell lines, indicating that the change in gene expression is not due to altered methylation (data not shown). This is consistent with the pseudohypoxic expression profile and absence of global hypermethylation observed in *DLST*-mutated tumors. It has been proposed that the shift from oxidative to glycolytic metabolism observed in esophageal squamous cell carcinoma cells could lead to global hypsuccinylation due to SucCoA depletion [10]. Our results suggest the existence of a feedback loop whereby reduced protein succinylation induces a similar metabolic shift towards a hypoxic state.

In conclusion, we show in this study that global protein succinylation levels depend strongly on DLST, advancing our understanding of this PTM's mechanistic role and highlighting DLST as a promising therapeutic target for treating diseases linked to dysregulated succinylation. Furthermore, we show that *DLST* mutations found in PPGL patients can remodel the cellular succinylome and cause a transcriptional shift from oxidative phosphorylation to a hypoxic cellular state.

## AUTHOR CONTRIBUTIONS

Sara Mellid contributed to experimental design, data acquisition, analysis, interpretation, and manuscript writing. Fernando García and Javier Muñoz contributed to data acquisition, analysis and interpretation. Alberto Díaz-Talavera and Ángel Mario Martínez-Montes contributed to bioinformatics and statistical analysis. Juan María Roldán-Romero, Eduardo Gil, Carlos Valdivia, Scherezade Jiménez, Manuel Pérez-Martínez, Ana Cerezo, Clara María Santiveri, Manel Esteller, Ramón Campos-Olivas and Javier Coloma helped conducting the experiments. Bruna Calsina, María Monteagudo, Rocío Letón, María Santos, Javier Lanillos, Natalia Martínez-Puente, Javier de Nicolás-Hernández, Emiliano Honrado and Eduardo Caleiras contributed to data analysis and interpretation. Cristina Montero-Conde, Luis Javier Leandro-García, Cristina Rodríguez-Antona and Mercedes Robledo provided suggestions and contributed to critical revision of the manuscript. Alberto Cascón contributed to the conception, experimental design, data interpretation, and critical revision of the manuscript. All authors reviewed and edited the manuscript. All authors read and approved the final manuscript.

## ACKNOWLEDGMENTS

The authors have nothing to report.

## CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

## FUNDING INFORMATION

This work was supported by the Instituto de Salud Carlos III (ISCIII) through the "Acción Estratégica en Salud" (AES) (projects PI18/00454 and PI22/01490 to A.C. and PI20/01169 to M.R.), cofounded by the European Regional Development Fund (ERDF). Sara Mellid was supported by the Spanish Ministry of Science, Innovation and Universities "Formación del Profesorado Universitario-FPU" fellowship with ID number FPU19/04940. Luis J. Leandro-García is supported by 'la Caixa' Foundation (ID 100010434) under agreement LCF/BQ/PI20/11760011.

## CONSENT FOR PUBLICATION

Not applicable.

## ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the ethics committee of Instituto de Salud Carlos III (CEI PI54\_2016-v2) and obtained patients' consent to participate.

**DATA AVAILABILITY STATEMENT**

Data and materials supporting these findings will be available upon reasonable request. The DNA methylation data are available in the National Center for Biotechnology Information GEO database under the accession numbers GSE210809, GSE111336 and GSE123185. The raw data of the RNA-seq used in this study are available in GEO under the accession number GSE210808 and in the European Genome-phenome archive under the accession number EGAS00001006044. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium with the dataset identifier PXD036782.

Sara Mellid<sup>1</sup>  
 Fernando García<sup>2</sup>  
 Luis Javier Leandro-García<sup>1</sup>  
 Alberto Díaz-Talavera<sup>1,3</sup>  
 Ángel Mario Martínez-Montes<sup>1</sup>  
 Eduardo Gil<sup>1</sup>  
 Bruna Calsina<sup>1</sup>  
 María Monteagudo<sup>1</sup>  
 Rocío Letón<sup>1</sup>  
 Juan María Roldán-Romero<sup>1</sup>  
 María Santos<sup>1</sup>  
 Javier Lanillos<sup>1</sup>  
 Carlos Valdivia<sup>1</sup>  
 Natalia Martínez-Puente<sup>1,3</sup>  
 Javier de Nicolás-Hernández<sup>1</sup>  
 Scherezade Jiménez<sup>4</sup>  
 Manuel Pérez-Martínez<sup>5</sup>   
 Emiliano Honrado<sup>6</sup>  
 Javier Coloma<sup>7</sup>  
 Ana Cerezo<sup>8</sup>  
 Clara María Santiveri<sup>9</sup>  
 Manel Esteller<sup>10,11,12,13</sup>  
 Ramón Campos-Olivas<sup>9</sup>  
 Eduardo Caleiras<sup>14</sup>  
 Cristina Montero-Conde<sup>1</sup>  
 Cristina Rodríguez-Antona<sup>1</sup>  
 Javier Muñoz<sup>2,15,16</sup>  
 Mercedes Robledo<sup>1,3</sup>  
 Alberto Cascón<sup>1,3</sup> 

<sup>1</sup>*Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>2</sup>*Proteomics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>3</sup>*Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain*

<sup>4</sup>*Monoclonal Antibodies Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>5</sup>*Confocal Microscopy Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>6</sup>*Anatomical Pathology Service, Hospital of León, León, Castilla y León, Spain*

<sup>7</sup>*Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>8</sup>*CNIO–Lilly Cell Signalling and Immunometabolism Section, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>9</sup>*Spectroscopy and Nuclear Magnetic Resonance Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>10</sup>*Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain*

<sup>11</sup>*Centro de Investigación Biomedica en Red Cancer (CIBERONC), Madrid, Spain*

<sup>12</sup>*Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain*

<sup>13</sup>*Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), L'Hospitalet, Barcelona, Spain*

<sup>14</sup>*Histopathology Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain*

<sup>15</sup>*Cell Signaling and Clinical Proteomics Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain*

<sup>16</sup>*Ikerbasque, Basque Foundation for Science, Bilbao, Spain*

**Correspondence**

Alberto Cascón, Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.  
 Email: [acascon@cnio.es](mailto:acascon@cnio.es)

**ORCID**

Manuel Pérez-Martínez  <https://orcid.org/0000-0001-8839-6895>

Alberto Cascón  <https://orcid.org/0000-0003-2119-891X>

**REFERENCES**

- Letouze E, Martinelli C, Lorient C, Burnichon N, Abermil N, Ottolenghi C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. *Cancer Cell*. 2013;23(6):739–52.
- Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Curras-Freixes M, et al. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. *Am J Hum Genet*. 2019;104(4):651–64.
- Zhang Z, Tan M, Xie Z, Dai L, Chen Y, Zhao Y. Identification of lysine succinylation as a new post-translational modification. *Nat Chem Biol*. 2011;7(1):58–63.
- Wang Y, Guo YR, Liu K, Yin Z, Liu R, Xia Y, et al. KAT2A coupled with the alpha-KGDH complex acts as a histone H3 succinyltransferase. *Nature*. 2017;552(7684):273–7.
- Zhao G, Zhen J, Liu X, Guo J, Li D, Xie J, et al. Protein post-translational modification by lysine succinylation: Biochemistry, biological implications, and therapeutic opportunities. *Genes Dis*. 2022.

6. Nagy B, Polak M, Ozohanics O, Zambo Z, Szabo E, Hubert A, et al. Structure of the dihydrolipoamide succinyltransferase (E2) component of the human alpha-ketoglutarate dehydrogenase complex (hKGDHc) revealed by cryo-EM and cross-linking mass spectrometry: Implications for the overall hKGDHc structure. *Biochim Biophys Acta Gen Subj*. 2021;1865(6):129889.
7. Gibson GE, Xu H, Chen HL, Chen W, Denton TT, Zhang S. Alpha-ketoglutarate dehydrogenase complex-dependent succinylation of proteins in neurons and neuronal cell lines. *J Neurochem*. 2015;134(1):86–96.
8. Lu K, Han D. A review of the mechanism of succinylation in cancer. *Medicine (Baltimore)*. 2022;101(45):e31493.
9. Whittle EF, Chilian M, Karimiani EG, Progri H, Buhás D, Kose M, et al. Biallelic variants in OGDH encoding oxoglutarate dehydrogenase lead to a neurodevelopmental disorder characterized by global developmental delay, movement disorder, and metabolic abnormalities. *Genet Med*. 2022;25(2):100332.
10. Guo Z, Pan F, Peng L, Tian S, Jiao J, Liao L, et al. Systematic Proteome and Lysine Succinylome Analysis Reveals Enhanced Cell Migration by Hyposuccinylation in Esophageal Squamous Cell Carcinoma. *Mol Cell Proteomics*. 2021;20:100053.

### SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.